Loading
Life sciences · Journal article
Discover Nano · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Exosomes have emerged as a promising class of next-generation nanocarriers at the intersection of regenerative medicine and drug delivery. Compared with conventional synthetic nanocarriers and stem cell-based therapies, exosomes offer unique advantages, including intrinsic biocompatibility, low immunogenicity, blood-barrier penetration, and natural intercellular cargo transfer. This review critically examines exosome biology, beginning with their biogenesis, structural composition, and roles in cellular homeostasis, immune regulation, autophagy, and tissue repair. Particular emphasis is placed on their therapeutic relevance in wound healing, neuroregeneration, cardiovascular repair, musculoskeletal regeneration, and cancer. The review further discusses major strategies for exosomal cargo engineering, including passive loading, electroporation, sonication, transfection-based approaches, extrusion, freeze–thaw treatment, and chemical functionalization. In addition, scaffold-assisted delivery systems and hybrid exosome–synthetic nanocarrier platforms are highlighted as important advances for improving local retention, targeting precision, and controlled release. Despite strong preclinical promise, translation remains limited by challenges in scalable manufacturing, purification, batch consistency, loading efficiency, potency assessment, and regulatory standardization. Future progress in this field will depend on the development of scalable and GMP-compatible exosome manufacturing, standardized purification and characterization methods, validated potency assays, regulatory-aligned quality control, and artificial intelligence (AI) engineering strategies to translate exosome-based platforms into safe, reproducible, and clinically effective regenerative therapeutics.